RadNet Reports Record Q1, Raises 2026 Revenue and Profit Guidance
RDNT sits 19% above its 52-week low of $50.76.
Summary
RadNet reported record first-quarter 2026 financial results, with total company revenue increasing 22.1% to $575.6 million and Adjusted EBITDA rising 36.3% to $63.3 million, surpassing earlier analyst expectations. This strong performance, driven by significant growth in advanced imaging and a 51.5% increase in Digital Health revenue, has led the company to revise its full-year 2026 guidance ranges upwards for revenue, Adjusted EBITDA, and free cash flow. This upward revision signals robust operational momentum and improved future profitability, serving as a significant positive catalyst for the stock. Investors will be watching for continued execution on new health system partnerships and the further integration and monetization of its Digital Health AI solutions.
At the time of this announcement, RDNT was trading at $60.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $50.76 to $85.84. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.